Hepatitis Clinical Trials

Showing 981-1000 of 2,113 trials

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

NCT00919633

The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with chronic hepatitis C infection as compared to patients who receive standard treatment.

Hepatitis C

Medtronic Corporate Technologies and New Ventures116 participantsStarted Jun 2009

Durham, North Carolina, United States

COMPLETEDPhase 1

A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects

NCT03662568

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of Morphothiadine Mesilate/Ritonavir combined with Entecavir or Tenofovir Disoproxil Fumarate in healthy subjects

Chronic Hepatitis B

Sunshine Lake Pharma Co., Ltd.56 participantsStarted Jun 2018

Changchun, Jilin, China

COMPLETED

Direct Acting Agents in Hepatitis C Patients

NCT03145844

This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.

Hepatitis CHepatitis C RelapseHepatitis C Recurrent

Fehmi Tabak2,700 participantsStarted Apr 2017

Istanbul, Turkey (Türkiye)

UNKNOWNPhase 2

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients

NCT04111367

This study was to assess the safety and efficacy of Seraprevir in combination with sofosbuvir in patients with Hepatitis C (HCV) genotype2,3,6. Efficacy was assessed by the rate of sustained viral response (SVR) 12 weeks after the discontinuation of therapy (SVR12).

Hepatitis C Virus Infection

Ginkgopharma CO., LTD36 participantsStarted Apr 2019

Beijing, Beijing Municipality, China • Liuchow, Guangxi, China • Changchun, Jilin, China +1 more locations

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects

Direct Acting Agents in Hepatitis C Patients

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients

Related Searches

Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study

Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years

The Patient-Reported Outcomes Project of HCV-TARGET

The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID

To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Helping Empower Liver and Kidney Patients

Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)

Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.

Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1